![Despite Equivalent Outcomes, Men Receive Neoadjuvant Chemotherapy Less Often Than Women for Lymph Node-Positive Breast Cancer | SpringerLink Despite Equivalent Outcomes, Men Receive Neoadjuvant Chemotherapy Less Often Than Women for Lymph Node-Positive Breast Cancer | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1245%2Fs10434-021-09994-w/MediaObjects/10434_2021_9994_Figa_HTML.png)
Despite Equivalent Outcomes, Men Receive Neoadjuvant Chemotherapy Less Often Than Women for Lymph Node-Positive Breast Cancer | SpringerLink
![PDF) Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials PDF) Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials](https://i1.rgstatic.net/publication/279304131_Outcome_after_neoadjuvant_chemotherapy_in_young_breast_cancer_patients_a_pooled_analysis_of_individual_patient_data_from_eight_prospectively_randomized_controlled_trials/links/56af21e308ae28588c62d2a7/largepreview.png)
PDF) Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials
![Cancers | Free Full-Text | Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer Cancers | Free Full-Text | Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer](https://pub.mdpi-res.com/cancers/cancers-14-05467/article_deploy/html/images/cancers-14-05467-g001.png?1667895565)
Cancers | Free Full-Text | Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer
![Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer - ScienceDirect Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0959804922000351-ga1.jpg)
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer - ScienceDirect
Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database | PLOS ONE
![Cureus | Role of Neoadjuvant Chemotherapy in Locally Advanced Carcinoma Stomach: An Analysis of the Short-Term Outcomes | Article Cureus | Role of Neoadjuvant Chemotherapy in Locally Advanced Carcinoma Stomach: An Analysis of the Short-Term Outcomes | Article](https://assets.cureus.com/uploads/figure/file/354088/lightbox_4213d030b05b11ecb54ad318665c4f09-Figure-1.png)
Cureus | Role of Neoadjuvant Chemotherapy in Locally Advanced Carcinoma Stomach: An Analysis of the Short-Term Outcomes | Article
![Long-term Results After Neoadjuvant Chemotherapy for Breast Cancer: A Single-center Experience | Anticancer Research Long-term Results After Neoadjuvant Chemotherapy for Breast Cancer: A Single-center Experience | Anticancer Research](https://ar.iiarjournals.org/content/anticanres/40/2/1079/F2.large.jpg)
Long-term Results After Neoadjuvant Chemotherapy for Breast Cancer: A Single-center Experience | Anticancer Research
![Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome | Nature Communications Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome | Nature Communications](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-020-19933-0/MediaObjects/41467_2020_19933_Fig1_HTML.png)
Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome | Nature Communications
![MRI to assess response after neoadjuvant chemotherapy in breast cancer subtypes: a systematic review and meta-analysis | npj Breast Cancer MRI to assess response after neoadjuvant chemotherapy in breast cancer subtypes: a systematic review and meta-analysis | npj Breast Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41523-022-00475-1/MediaObjects/41523_2022_475_Fig1_HTML.png)
MRI to assess response after neoadjuvant chemotherapy in breast cancer subtypes: a systematic review and meta-analysis | npj Breast Cancer
![Cancers | Free Full-Text | Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine Cancers | Free Full-Text | Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine](https://www.mdpi.com/cancers/cancers-14-03876/article_deploy/html/images/cancers-14-03876-g001.png)
Cancers | Free Full-Text | Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine
![Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy: a retrospective cohort analysis | BMC Cancer | Full Text Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy: a retrospective cohort analysis | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-019-5499-2/MediaObjects/12885_2019_5499_Fig3_HTML.png)
Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy: a retrospective cohort analysis | BMC Cancer | Full Text
![Frontiers | Advances in Imaging in Evaluating the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer Frontiers | Advances in Imaging in Evaluating the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer](https://www.frontiersin.org/files/Articles/816297/fonc-12-816297-HTML/image_m/fonc-12-816297-g001.jpg)
Frontiers | Advances in Imaging in Evaluating the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer
![Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer in: Journal of the National Comprehensive Cancer Network Volume 15 Issue 10 (2017) Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer in: Journal of the National Comprehensive Cancer Network Volume 15 Issue 10 (2017)](https://jnccn.org/view/journals/jnccn/15/10/1216fig04.jpeg)
Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer in: Journal of the National Comprehensive Cancer Network Volume 15 Issue 10 (2017)
![Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials - The Lancet Oncology Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials - The Lancet Oncology](https://www.thelancet.com/cms/attachment/04828f61-596a-4e20-8bd5-ddb7d270a44a/gr1_lrg.jpg)
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials - The Lancet Oncology
Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database | PLOS ONE
![FZR1 as a novel biomarker for breast cancer neoadjuvant chemotherapy prediction | Cell Death & Disease FZR1 as a novel biomarker for breast cancer neoadjuvant chemotherapy prediction | Cell Death & Disease](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41419-020-03004-9/MediaObjects/41419_2020_3004_Fig1_HTML.png)
FZR1 as a novel biomarker for breast cancer neoadjuvant chemotherapy prediction | Cell Death & Disease
![Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer: A network meta-analysis - eClinicalMedicine Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer: A network meta-analysis - eClinicalMedicine](https://www.thelancet.com/cms/asset/32e9db11-f570-4d13-b53a-f0f642d88d11/gr1.jpg)
Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer: A network meta-analysis - eClinicalMedicine
![Imaging, biomarkers after first neoadjuvant chemotherapy treatment cycle predicts treatment outcome, study finds | McKelvey School of Engineering at Washington University in St. Louis Imaging, biomarkers after first neoadjuvant chemotherapy treatment cycle predicts treatment outcome, study finds | McKelvey School of Engineering at Washington University in St. Louis](https://engineering.wustl.edu/news/images/imgix/Zhu-figure.jpg)
Imaging, biomarkers after first neoadjuvant chemotherapy treatment cycle predicts treatment outcome, study finds | McKelvey School of Engineering at Washington University in St. Louis
![Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges - Annals of Oncology Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges - Annals of Oncology](https://www.annalsofoncology.org/cms/asset/feb89e2f-7a4a-4eeb-b6fc-b1caf5a359af/gr3.jpg)